SLNO Projected Dividend Yield
Soleno Therapeutics Inc ( NASDAQ : SLNO )Soleno Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare diseases. Co.'s primary candidate is Diazoxide Choline Extended-Release tablets (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS). DCCR has orphan designation for the treatment of PWS in the U.S. as well as in the European Union. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. 20 YEAR PERFORMANCE RESULTS |
SLNO Dividend History Detail SLNO Dividend News SLNO Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |